Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares saw strong trading volume on Thursday . 689,910 shares were traded during trading, a decline of 19% from the previous session’s volume of 848,702 shares.The stock last traded at $49.31 and had previously closed at $50.85.

Several analysts recently weighed in on the company. Credit Suisse Group AG reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday. Wedbush reissued an “outperform” rating and set a $92.00 price target (down from $99.00) on shares of Ultragenyx Pharmaceutical in a report on Tuesday, May 10th. Zacks Investment Research raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Wednesday, May 4th. Jefferies Group reaffirmed a “buy” rating and issued a $109.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, June 8th. Finally, Canaccord Genuity reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, May 10th. Three research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Ultragenyx Pharmaceutical has a consensus rating of “Buy” and a consensus price target of $98.09.

The stock’s market cap is $1.93 billion. The firm has a 50 day moving average price of $58.50 and a 200 day moving average price of $65.60.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Monday, May 9th. The biopharmaceutical company reported ($1.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.29) by $0.06. During the same period in the previous year, the firm posted ($0.63) earnings per share. The business’s quarterly revenue was up .0% on a year-over-year basis. Equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post ($5.84) earnings per share for the current fiscal year.

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction on Monday, May 16th. The stock was sold at an average price of $59.95, for a total transaction of $1,199,000.00. Following the sale, the chief executive officer now owns 526,704 shares in the company, valued at $31,575,904.80. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Sunil Agarwal sold 650 shares of the stock in a transaction on Monday, June 20th. The stock was sold at an average price of $54.16, for a total value of $35,204.00. The disclosure for this sale can be found here.

Several large investors have modified their holdings of the company. Mutual of America Capital Management LLC increased its stake in shares of Ultragenyx Pharmaceutical by 1.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 33,497 shares of the biopharmaceutical company’s stock worth $3,758,000 after buying an additional 497 shares during the period. Swiss National Bank increased its stake in shares of Ultragenyx Pharmaceutical by 1.4% in the fourth quarter. Swiss National Bank now owns 35,367 shares of the biopharmaceutical company’s stock worth $3,967,000 after buying an additional 500 shares during the period. GSA Capital Partners LLP increased its stake in shares of Ultragenyx Pharmaceutical by 12.2% in the fourth quarter. GSA Capital Partners LLP now owns 11,188 shares of the biopharmaceutical company’s stock worth $1,255,000 after buying an additional 1,218 shares during the period. State Board of Administration of Florida Retirement System increased its stake in shares of Ultragenyx Pharmaceutical by 6.7% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 22,007 shares of the biopharmaceutical company’s stock worth $2,469,000 after buying an additional 1,390 shares during the period. Finally, Paradigm Asset Management Co. LLC increased its stake in shares of Ultragenyx Pharmaceutical by 39.0% in the fourth quarter. Paradigm Asset Management Co. LLC now owns 9,450 shares of the biopharmaceutical company’s stock worth $1,060,000 after buying an additional 2,650 shares during the period.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.